Exploring the Impact of Immunotherapy on Cancer Recurrence

  • Unique Paper ID: 176384
  • Volume: 11
  • Issue: 11
  • PageNo: 6229-6234
  • Abstract:
  • The body's inherent defenses against cancer were known long before the modern era, as evidenced by numerous anecdotal accounts of tumors magically vanishing, sometimes on their own or following an infectious or feverish event. It is now widely acknowledged that immunosuppression is linked to an increased risk of cancer, and spontaneous tumor regression of untreated malignant tumors is a rare but well-accepted phenomena.Biologic modifiers, such as cytokines and vaccines, adoptive cell therapies, oncolytic viruses, and antibodies against immune checkpoint inhibitors, such as the co-inhibitory T-cell receptor PD-1 and one of its ligands, programmed death-ligand 1, are among the various forms of cancer immunotherapies covered here.(1) As a result of the tremendous advancements in cancer research over the years, immunotherapy has become a significant cancer therapies. Immunotherapy has shown promising results and presents a practical approach to significantly increase the overall survival rate of cancer patients while also improving their quality of life. This systematic review's goal was to evaluate immunotherapy's effectiveness in treating cancer.

Copyright & License

Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

BibTeX

@article{176384,
        author = {Amruta Dadasaheb Kalunkhe and Dr.Vaishali Pardeshi and Dr.Sonia Singh and Dr.Ganesh Andhale and Dr.Madhuri Shelar},
        title = {Exploring the Impact of Immunotherapy on Cancer Recurrence},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {11},
        number = {11},
        pages = {6229-6234},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=176384},
        abstract = {The body's inherent defenses against cancer were known long before the modern era, as evidenced by numerous anecdotal accounts of tumors magically vanishing, sometimes on their own or following an infectious or feverish event. It is now widely acknowledged that immunosuppression is linked to an increased risk of cancer, and spontaneous tumor regression of untreated malignant tumors is a rare but well-accepted phenomena.Biologic modifiers, such as cytokines and vaccines, adoptive cell therapies, oncolytic viruses, and antibodies against immune checkpoint inhibitors, such as the co-inhibitory T-cell receptor PD-1 and one of its ligands, programmed death-ligand 1, are among the various forms of cancer immunotherapies covered here.(1) As a result of the tremendous advancements in cancer research over the years, immunotherapy has become a significant cancer therapies. Immunotherapy has shown promising results and presents a practical approach to significantly increase the overall survival rate of cancer patients while also improving their quality of life. This systematic review's goal was to evaluate immunotherapy's effectiveness in treating cancer.},
        keywords = {Active immunotherapy, passive Immunotherapy, Adaptive cell therapy, cancer immunotherapy, cancer vaccines.},
        month = {April},
        }

Cite This Article

  • ISSN: 2349-6002
  • Volume: 11
  • Issue: 11
  • PageNo: 6229-6234

Exploring the Impact of Immunotherapy on Cancer Recurrence

Related Articles